GlaxoSmithKline Research Centre Limited, Prilaz baruna Filipovića 29, HR-10000 Zagreb, Croatia.
Bioorg Med Chem. 2013 Jan 1;21(1):321-32. doi: 10.1016/j.bmc.2012.10.036. Epub 2012 Oct 30.
A new concept in design of safe glucocorticoid therapy was introduced by conjugating potent glucocorticoid steroids with macrolides (macrolactonolides). These compounds were synthesized from various steroid 17β-carboxylic acids and 9a-N-(3-aminoalkyl) derivatives of 9-deokso-9a-aza-9a-homoeritromicin A and 3-descladinosyl-9-deokso-9a-aza-9a-homoeritromicin A using stable alkyl chain. Combining property of macrolides to preferentially accumulate in immune cells, especially in phagocyte cells, with anti-inflammatory activity of classic steroids, we designed molecules which showed good anti-inflammatory activity in ovalbumin (OVA) induced asthma in rats. The synthesis, in vitro and in vivo anti-inflammatory activity of this novel class of compounds are described.
一种新的安全糖皮质激素治疗设计理念是通过将强效糖皮质激素与大环内酯类药物(大环内酯内酯)偶联而引入的。这些化合物是由各种甾体 17β-羧酸和 9a-N-(3-氨基烷基)衍生物合成的,9-deokso-9a-aza-9a-homoeritromicin A 和 3-descladinosyl-9-deokso-9a-aza-9a-homoeritromicin A 使用稳定的烷基链。结合大环内酯类药物优先在免疫细胞(尤其是吞噬细胞)中积累的特性和经典类固醇的抗炎活性,我们设计了在卵清蛋白(OVA)诱导的大鼠哮喘中具有良好抗炎活性的分子。本文描述了该新型化合物的合成、体外和体内抗炎活性。